Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70

BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.
byBenzinga Newsdesk
December 12, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts